Skip to main content
Skip main navigationClose Drawer MenuOpen Drawer Menu

Caffeine and Arrhythmias: Time to Grind the DataFree Access

State-of-the-Art Review

J Am Coll Cardiol EP, 4 (4) 425–432

Central Illustration


The interaction between arrhythmia episodes and certain lifestyle factors such as obesity and alcohol is well established. There is significant public and professional interest in the role of caffeinated beverages such as coffee, tea, and energy drinks in cardiovascular health. However, many widely held beliefs are not supported by evidence. This study provides a comprehensive review of the impact of caffeinated beverages on cardiac rhythm.


The importance of lifestyle-related risk factors is increasingly recognized in the management of atrial fibrillation (1), and there is considerable public interest in the impact of coffee, tea, and energy drinks (EDs) in arrhythmogenesis. The latest American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines for management of patients with atrial fibrillation (2) and ventricular arrhythmia (VA) (3) address the role of alcohol as a potential trigger for arrhythmias, however, they do not refer to caffeinated beverages, which are equally ubiquitous in Western culture. Coffee is a stimulant and is the most common form of cognitive enhancement (4). It has been assumed that, because of the effects of caffeine on enhancing the mind and heart rate, it may contribute to arrhythmia. This public perception is often based on anecdotal experience; however, the perception extends to the medical community, with more than 80% of U.S. physicians recommending abstinence or reduction in caffeine intake for patients with palpitations or documented arrhythmias (5). Extensive research over the past decade suggests that many widely held beliefs regarding caffeine may not be evidence-based. This study performed a detailed review of published reports to determine the interactions between coffee, tea, and EDs and rhythm disorders.


We performed a comprehensive search of Medline, EMBASE, Web of Science, and PubMed, focusing on human and animal studies published in English that examined the effects of caffeine on both atrial arrhythmias and VAs. Prospective, retrospective, observational, and interventional studies were all included in the search. Key search terms were “caffeine,” “coffee,” “tea,” and “energy drinks” in combination with “arrhythmias,” “atrial fibrillation,” “sudden death,” “ectopy,” and “ventricular arrhythmias.” Conference abstracts were excluded. No restriction was placed on the year of study publication.

Caffeine pharmacology

Caffeine is the primary constituent in coffee (1 cup of coffee contains ∼95 mg of caffeine) and is also found in tea, soft drinks, and EDs (Table 1). It acts as a methylxanthine alkaloid and central nervous system stimulant. Caffeine’s half-life is 5.7 h, with nearly 100% bioavailability, and maximum concentrations are reached within 1 h of consumption (6).

Table 1. Caffeine Content of Common Commercially Available Caffeinated Beverages

BeverageAmount of Caffeine, mgVolume, ml
Can of Coca Cola32375
Cup of Lipton green tea35150
Cup of Lipton black tea55150
Starbucks Café Latte – short75236
Espresso shot10625
Starbucks Café Latte – grande150473
Monster Energy drink160473
Wired X344 Energy drink344473
Fixx Energy drink500591

Coca Cola, Inc., Atlanta, Georgia; Fixx Beverage, LLC, Toms River, New Jersey; Lipton, Unilever Australia, Sydney, New South Wales, Australia; Monster, Hansen Natural Corporation, Corona, California; Starbucks, Tacoma, Washington; Wired, Wired Energy Drinks, Everett, Washington.

Caffeine has a range of effects on sympathetic activation, intracellular calcium trafficking, adenosine receptors, and is an antioxidant. Caffeine increases the sinus rate by sympathomimetic effects mediated by phosphodiesterase inhibition and a rise in cytosolic calcium concentration by blocking calcium reuptake into the sarcoplasmic reticulum (Central Illustration) (7). An increase in intracellular calcium has the potential to induce atrial arrhythmia by enhancing automaticity of atrial pacemaker cells and after depolarization-induced triggered activity (8). A dose of 250 mg of caffeine (3 cups of coffee) acutely increases norepinephrine and epinephrine by 75% and 207%, respectively (9). At very high doses, caffeine may be proarrhythmic. In a murine study, the administration of 15 mg/kg per min caffeine resulted in sympathetic over-activation, with sinus tachycardia and ventricular ectopy culminating in ventricular fibrillation (VF) in all rats. Effects were partially reversed by administration of beta-blockers (10).

Central Illustration.
Central Illustration.

Effects of Caffeine at a Cellular Level

5’-AMP = 5’-adenosine monophosphate; AC = adenylate cyclase; ADP = adenosine diphosphate; AR = adenosine receptor; ATP = adenosine triphosphate; Ca2+ = calcium; cAMP = cyclic adenosine monophosphate; Gi = inhibitory regulative G-protein; Gs = stimulative regulative G-protein; PDE = cyclic nucleotide phosphodiesterase; PKA = protein kinase A; Ryr = Ryanodine receptor; SERCA = sarcoendoplasmic reticulum calcium transport ATPase.

Proposed antiarrhythmic properties of caffeine may be mediated in part by nonselective inhibition of adenosine A1 and A2A receptors (11). Adenosine shortens atrial refractoriness and may trigger atrial fibrillation during acute administration (12). In addition, caffeine and the polyphenols found in coffee have antioxidant properties that may bind reactive oxidant species responsible for adverse atrial remodelling and atrial fibrillation (AF) (13). In fact, coffee has a higher level of antioxidant activity (292 to 948 min) than black tea (67 to 277 min) or herbal tea (6 to 78 min), on the basis of a cup serving (14). As such there are putative mechanisms by which caffeine may enhance or reduce arrhythmogenesis.

Coffee and atrial arrhythmia

Experiment- and population-based studies have sought to determine the impact of caffeine on heart rhythm disorders. In a canine model, an intravenous injection of 1 to 5 mg/kg of caffeine unexpectedly reduced AF inducibility (15). In a human study, Lemery et al. (16) administered 5 mg/kg caffeine over 57 ± 13 min before electrophysiology study in patients with supraventricular tachycardia (SVT) and were unable to demonstrate an effect on atrial or ventricular refractory periods or the inducibility of SVT. Dobmeyer et al. (17) also failed to show short-term effects on interatrial and intra-atrial conduction in humans. In a community-based cohort of 1,388 participants undergoing 24-h Holter monitoring, Dixit et al. (18) failed to demonstrate any association between higher caffeine intake and atrial or ventricular premature beats. Single high-dose caffeine (400 mg) did not affect electrocardiographic P-wave duration or P-wave dispersion in healthy volunteers (19). To date, clinical studies have failed to show deleterious effects of caffeine on atrial and ventricular electrophysiologic properties.

Population-based studies have consistently demonstrated a reduction in atrial fibrillation with increasing levels of caffeine ingestion. Incident AF events in 57,053 participants followed for 13.5 years were lower in habitual coffee drinkers at all levels of consumption (hazard ratio [HR]: 0.79 for 6 to 7 cups per day) (20). A meta-analysis of 6 prospective cohort studies with 228,465 participants similarly demonstrated an inverse relationship, with AF incidence decreasing by 6% for every 300 mg/day increment in regular caffeine intake (21). In a further meta-analysis of 115,993 patients, pooled results demonstrated a significant 13% reduction in incident AF risk (22). In a population-based study of 130,054 people, 3,137 subjects (2.4%) were hospitalized for arrhythmia over 17.6 years’ follow-up. Caffeine intake was again inversely related to arrhythmia risk (HR highest vs. lowest quartile = 0.6; p = 0.03) (23).

Table 2 summarizes 11 major human studies (360,980 patients, 15,198 AF cases) examining the relationship between caffeinated beverages and atrial arrhythmia. One small case-control study with no adjustments for other confounders (24) reported coffee was detrimental, whereas 3 studies consistently demonstrated a benefit, and the remaining studies showed no significant interaction.

Table 2. Major Studies Examining Impact of Caffeinated Beverages on Atrial Arrhythmia

First Author (Ref. #), YearCases/Participants% MalesAge, yrsFollow-Up, yrsStudy DesignKey Findings
Mostofsky et al. (20), 20163,415/57,0534856.7 ± 4.413.5Population-based cohort study

Higher coffee intake was associated with lower rate of incident AF (linear trend: p = 0.02).

Compared to nondrinkers, OR: 0.86 (95% CI: 0.71 to 1.04) for 2–3 cups per day, and OR: 0.79 (95% CI: 0.64 to 0.98) for 6–7 cups per day

Dixit et al. (18), 20161,3884771.9 ± 5.0NAObservational study (24-h Holter)

No correlation between atrial ectopics/h and intake of coffee (p = 0.28) or tea (p = 0.57).

No correlation between SVT runs and intake of coffee (p = 0.22) or tea (p = 0.90).

Liu et al. (39), 2016401/8015663.0 ± 1.2Case control

Green tea was protective against incident AF (multivariate OR: 0.349; 95% CI: 0.25 to 0.48) in a dose-dependent manner (p for trend = 0.001).

Larsson et al. (56), 20157,041/76,4755561.512Population-based cohort study

No association between coffee consumption and risk of incident AF at all levels of consumption (multivariate RR: 0.98 for 2–3 cups/day; RR: 1.01 for ≥5 cups/day; p = 0.64 for trend).

Klatsky et al. (23), 20111,512/13,00544417.6Retrospective population cohort

Higher coffee intake was associated with lower rates of hospitalization for AF (HR: 0.81; 95% CI: 0.69 to 0.96 for ≥4 cups/day) and SVT (HR: 0.63; 95% CI: 0.41 to 0.98 for ≥4 cups/day)

Shen et al. (57), 2011296/4,5264462 ± 104.0Prospective cohort

No correlation between caffeine intake and risk of incident AF (for quartiles of intake for Q1 HR: 0.84; 95% CI: 0.62 to 1.15 vs. Q4 HR: 0.98; 95% CI: 0.7 to 1.39; p for trend = 0.84).

Conen et al. (58), 2010945/33,63805314.4Prospective cohort

U-shaped relationship with lowest risk of incident AF in third quintile of intake with median 285 mg/day (HR: 0.78; 95% CI: 0.64 to 0.95; p for quadratic trend = 0.03).

None of the individual caffeine components (tea, coffee, cola, chocolate) was associated with incident AF.

Mukamal, et al. (59), 2009163/1,3697059.86.9–9.9Prospective cohort

In patients with previous myocardial infarction, coffee drinkers in the 4 higher categories of intake had ∼30% lower risk of developing AF (HR for ≥1 cups/day: 0.65; 95% CI: 0.40 to 1.05).

Frost et al. (60), 2006555/47,94947565.7Prospective cohort

Compared with the lowest quintile, there was no association between caffeine intake and incident AF (lowest risk was third quintile, ∼584 mg/day; HR: 0.85 (95% CI: 0.65 to 1.12).

Mattioli et al. (24), 2005116/2327454 ± 7Case control

High coffee intake, >3 cups/day, was associated with a lower rate of spontaneous cardioversion from AF (OR: 0.3; 95% CI: 0.11 to 0.49; p = 0.008).

Wilhelmsenet al. (61), 2001754/7,49510047 ± 5525.2Population-based cohort study

Consumption of ≥5 cups/day was not associated with a higher risk of incident AF (OR: 1.09; 95% CI: 0.87 to 1.38), although moderate consumption reached borderline significance (OR: 1.24; 95% CI: 1.00 to 1.54).

AF = atrial fibrillation; CI = confidence interval; HR = hazard ratio; NA = not applicable; OR = odds ratio; RR = relative risk; SVT = supraventricular tachycardia.

Nevertheless, one must exercise caution when extrapolating data from healthy volunteers and registries to individual patients. In all long-term observational studies, investigators followed regular long-term coffee drinkers; and caffeine tolerance may explain the lack of association with arrhythmias. Moreover, there may be individual differences in susceptibility to the effects of caffeine on electrophysiologic and autonomic factors that trigger arrhythmias in some people. Twenty-five percent of patients report coffee is an AF trigger (25), and those with a clear temporal association between coffee intake and documented AF episodes should accordingly be counseled to abstain.

Coffee and ventricular arrhythmia

Caffeine does not appear to increase the likelihood of VA. A study of 22 patients with a history of VAs who underwent electrophysiological study before and 1 h post-coffee (275 mg caffeine) ingestion demonstrated no significant difference in inducibility of VAs (26). In 5 placebo-controlled trials, caffeine in doses of up to 500 mg daily (∼6 cups of coffee) did not experience an increase in the severity or frequency of VAs (27). In 50 consecutive patients with a history of malignant VAs receiving either coffee (containing 200 mg of caffeine) or a decaffeinated drink, there were no significant differences observed in ventricular ectopy or tachycardia, despite increases in serum catecholamine levels in the caffeinated group (28). A meta-analysis of 7 human studies found that caffeine consumption had no impact on incidence of ventricular ectopy (29).

Numerous randomized studies have explored the impact of caffeine intake and restriction on VAs. In a randomized study of 103 patients with post-myocardial infarction, regular caffeine (average: 353 mg/day) resulted in improved heart rate variability, increased parasympathetic activity, and no significant arrhythmias compared with controls (30). More recently, Zuchinali et al. (31) performed a double-blinded crossover trial in 51 patients with moderate-to-severe left ventricle dysfunction at high risk of VAs, consuming either 500 mg of caffeine or placebo. No significant differences were observed in supraventricular or ventricular ectopy, nor nonsustained ventricular tachycardia during continuous monitoring at rest and with exercise. In a randomized double-blind trial of caffeine restriction using decaffeinated coffee in patients with symptomatic ventricular premature beats, no significant changes were seen in palpitation scores or ectopic burden (32). Moreover, large epidemiological studies suggest that regular caffeine drinkers have lower cardiovascular (33) and all-cause mortality (34), with a potentially attenuated risk of coronary heart disease, heart failure, and stroke.

A summary of major human studies examining coffee consumption and VAs is presented in Table 3. Of 8 studies involving 232,717 patients, 6 studies demonstrated no association, including 3 well-designed prospective trials (28,29,35). Only 2 older studies (a case-control and a cross-sectional survey) demonstrated an association between coffee consumption and VAs at very high levels of coffee intake only (>10 cups per day [36] and >9 cups per day [37], respectively).

Table 3. Major Studies Examining Impact of Caffeinated Beverages on Ventricular Arrhythmia

First Author (Ref. #), YearCases/Participants% of MalesAge, yrsFollow-Up, yrsStudy DesignKey Findings
Dixit et al. (18), 20161,3884771.9 ± 5.0NAObservational study (24-h Holter)

No correlation between VPBs/h and intake of coffee (p = 0.86) or tea (p = 0.32).

No correlation between VT runs and intake of coffee (p = 0.57) or tea (p = 0.13).

Zuchinali et al. (29), 2016517460.6 ± 10.9NARandomized controlled trial

Acute caffeine ingestion (500 mg over 5 h) vs. placebo did not increase VPBs (185 vs. 239, respectively; p = 0.47) or nonsustained VT in patients with moderate to severe LV dysfunction.

Bertoia et al. (62), 2013239/93,676063.5 ± 7.411Prospective cohort study

No association between total intake of caffeine (p for trend = 0.52), coffee (p for trend = 0.84), and caffeinated tea (p for trend = 0.30) and risk of SCD.

Klatsky et al. (23), 2011323/1,300544417.6Retrospective population cohort

Higher coffee intake was not associated with higher risk of VT (HR: 1.05; 95% CI: 0.98 to 1.12), with a trend toward lower risk of ventricular fibrillation/SCD (HR: 0.88; 95% CI: 0.78 to 1.00).

de Vreede-Swagemakers et al. (36), 19991178465 ± 7NACase control

Only very heavy coffee consumption (>10 cups per day) was associated with a higher risk of SCD (OR: 55.7; 95% CI: 6.4 to 483); however, 1–9 cups per day was not a significant predictor.

Graboys et al. (28), 1989507661NACrossover trial

In patients with structural heart disease, hourly VPB burden and nonsustained VT did not differ between the caffeine and placebo trials (despite elevated catecholamine levels in the caffeine arm).

Myers et al. (35), 1987707958 ± 2NARandomized double-blind trial

In 7-day post-myocardial infarction patients, continuous Holter monitoring did not show a difference in percentage of patients who had VPBs, nor VPB burden after 300 mg of caffeine vs. placebo (despite rises in blood pressure and catecholamine levels in the caffeine group).

Prineas et al. (37), 19807,31110037–57NACross-sectional survey

Compared with consumption of ≤2 drinks per day, coffee (t = 2.90; p < 0.005) and tea (t = 3.78; p < 0.001) were positively associated with the presence of VPBs, with >9 cups of coffee associated with twice the risk of VPBs in healthy patients.

LV = left ventricle; SCD = sudden cardiac death; VPB = ventricular premature beats; VT = ventricular tachycardia; other abbreviations as in Table 2.


There are limited observational data suggesting that tea (particularly green tea) may be beneficial. Tea contains less caffeine than coffee and is rich in epigallocatechin gallate (EGCG), a catechin with antioxidant and anti-inflammatory properties. In a rabbit model, supplementation with EGCG was associated with prolongation of an atrial effective refractory period together with a reduction in AF inducibility and atrial fibrosis (38). In a case-control study of 801 subjects, green tea intake led to a significant reduction in paroxysmal and persistent AF (odds ratio [OR]: 0.35; 95% confidence interval [CI]: 0.25 to 0.48) (39).

Benefits of tea may also extend to reducing VAs. In a rat model, pre-treatment for 4 weeks of black tea consumption raised the threshold dose of aconitine for inducing VT (p < 0.001) and significantly reduced duration of VT and VF compared with those of controls (40). In humans, moderate tea consumption (up to 14 cups/week) was associated with a significant reduction in VAs (OR: 0.7; 95% CI: 0.6 to 0.9) in 3,882 patients following myocardial infarction (41). In a meta-analysis, consumption of 3 cups of tea per day significantly reduced the risk of cardiac death (relative risk 0.74; 95% CI: 0.63 to 0.86) (42).

Energy drinks

EDs often contain caffeine at significantly higher concentrations than coffee and tea, which have inhibitory effects on phosphodiesterases, promoting calcium release from intracellular stores and increasing myofilament sensitivity to calcium, mimicking the effects of adrenaline (43). Proarrhythmic effects may be augmented by other energy-boosting substances, such as guarana, sugar, ginseng, yohimbine, and ephedra (44), as well as by concurrent intake of alcohol and illicit drugs. Guarana, particularly, has a higher caffeine concentration than coffee and contains theophylline, which also has stimulant properties (45).

There have been increasing numbers of case reports relating to the temporal association between EDs and arrhythmias, including young patients without structural heart disease presenting with AF, SVT, VT, and VF shortly after consuming these beverages (46). Three quarters of patients who consumed 2 or more EDs/day reported palpitations within 24 h, compared with only 12% of occasional consumers (p < 0.001) (47).

In observational studies, EDs have been shown to lower heart rate variability (48) and prolong QTc interval (49). In patients with congenital long-QT syndrome, dangerous QTc prolongation of ≥50 ms following ED consumption has been reported (50). There are isolated case reports of EDs unmasking long QT and Brugada syndromes (51). ED ingredients other than caffeine are responsible for the prolongation of QTc interval. In a randomized, double-blind crossover study in 18 healthy individuals who consumed either ED or caffeinated controls (each containing 320 mg of caffeine), significant QTc prolongation (0.44 ± 18.4 ms vs. −10.4 ± 14.8 ms, respectively; p = 0.02) was demonstrated in the ED group (52).

EDs may be responsible for a prothrombotic state, particularly relevant in patients with pre-existing structural heart disease or AF. Studies in healthy volunteers undergoing platelet function testing before and 60 min after ED consumption demonstrated a significant increase in platelet aggregation through arachidonic acid-induced activation (53) and endothelial dysfunction (54).

The concerns regarding the potential deleterious effects of EDs have been expressed in public policy. The U.S. Food and Drug Administration has forced companies to include conventional nutritional fact panels with exact caffeine concentrations, following the reclassification of EDs as “beverages” rather than “dietary supplements” in an attempt to improve consumer safety. The International Society of Sports Nutrition recommends that patients with pre-existing cardiovascular conditions who are taking medications that may be affected by caffeine and other stimulants refrain from use of EDs, and they warn that more than 1 ED/day, even in healthy individuals, may be harmful (55).


Many clinicians continue to counsel patients with atrial or VAs to avoid all caffeinated beverages, particularly coffee, despite an absence of evidence to support this approach. If, in individual cases where a clear temporal association between arrhythmia episodes and caffeine intake is apparent, then avoidance is sensible. Large-scale population-based studies and randomized controlled trials suggest coffee and tea are safe and may even reduce the incidence of arrhythmia. Although there is no clearly defined threshold for caffeine harm, a regular intake of up to 300 mg/day appears to be safe and may even be protective against heart rhythm disorders.

  • 1. Voskoboinik A., Prabhu S., Ling L.H., Kalman J.M. and Kistler P.M. : "Alcohol and atrial fibrillation: a sobering review". J Am Coll Cardiol 2016; 68: 2567.

    View ArticleGoogle Scholar
  • 2. January C.T., Wann L.S., Alpert al. : "2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society". J Am Coll Cardiol 2014; 64: 1.

    View ArticleGoogle Scholar
  • 3. Al-Khatib S.M., Stevenson W.G., Ackerman al. : "2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society". J Am Coll Cardiol 2017 Oct 24; . [E-pub ahead of print]..

    Google Scholar
  • 4. Brice C.F. and Smith A.P. : "Effects of caffeine on mood and performance: a study of realistic consumption". Psychopharmacology (Berl) 2002; 164: 188.

    CrossrefMedlineGoogle Scholar
  • 5. Hughes J.R., Amori G. and Hatsukami D.K. : "A survey of physician advice about caffeine". J Subst Abuse 1988; 1: 67.

    CrossrefMedlineGoogle Scholar
  • 6. Statland B.E. and Demas T.J. : "Serum caffeine half-lives. Healthy subjects vs. patients having alcoholic hepatic disease". Am J Clin Pathol 1980; 73: 390.

    CrossrefMedlineGoogle Scholar
  • 7. O'Neill S.C. and Eisner D.A. : "A mechanism for the effects of caffeine on Ca2+ release during diastole and systole in isolated rat ventricular myocytes". J Physiol 1990; 430: 519.

    CrossrefMedlineGoogle Scholar
  • 8. Artin B., Singh M., Richeh C., Jawad E., Arora R. and Khosla S. : "Caffeine-related atrial fibrillation". Am J Ther 2010 Sep-Oct; 17: 169.

    CrossrefGoogle Scholar
  • 9. Robertson D., Frölich J.C., Carr al. : "Effects of caffeine on plasma renin activity, catecholamines and blood pressure". N Engl J Med 1978; 298: 181.

    CrossrefMedlineGoogle Scholar
  • 10. Strubelt O. and Diederich K.W. : "Experimental treatment of the acute cardiovascular toxicity of caffeine". J Toxicol Clin Toxicol 1999; 37: 29.

    CrossrefMedlineGoogle Scholar
  • 11. Conlay L.A., Conant J.A., deBros F. and Wurtman R. : "Caffeine alters plasma adenosine levels". Nature 1997; 389: 136.

    CrossrefMedlineGoogle Scholar
  • 12. Kabell G., Buchanan L.V., Gibson J.K. and Belardinelli L. : "Effects of adenosine on atrial refractoriness and arrhythmias". Cardiovasc Res 1994; 28: 1385.

    CrossrefMedlineGoogle Scholar
  • 13. Metro D., Cernaro V., Santoro al. : "Beneficial effects of oral pure caffeine on oxidative stress". J Clin Transl Endocrinol 2017; 10: 22.

    MedlineGoogle Scholar
  • 14. Richelle M., Tavazzi I. and Offord E. : "Comparison of the antioxidant activity of commonly consumed polyphenolic beverages (coffee, cocoa, and tea) prepared per cup serving". J Agric Food Chem 2001; 49: 3438.

    CrossrefMedlineGoogle Scholar
  • 15. Rashid A., Hines M., Scherlag B.J., Yamanashi W.S. and Lovallo W. : "The effects of caffeine on the inducibility of atrial fibrillation". J Electrocardiol 2006; 39: 421.

    CrossrefMedlineGoogle Scholar
  • 16. Lemery R., Pecarskie A., Bernick J., Williams K. and Wells G.A. : "A prospective placebo controlled randomized study of caffeine in patients with supraventricular tachycardia undergoing electrophysiologic testing". J Cardiovasc Electrophysiol 2015; 26: 1.

    CrossrefMedlineGoogle Scholar
  • 17. Dobmeyer D.J., Stine R.A., Leier al. : "The arrhythmogenic effects of caffeine in human beings". N Engl J Med 1983; 308: 814.

    CrossrefMedlineGoogle Scholar
  • 18. Dixit S., Stein P.K., Dewland al. : "Consumption of caffeinated products and cardiac ectopy". J Am Heart Assoc 2016; 5: 002503.

    CrossrefGoogle Scholar
  • 19. Caron M.F., Song J., Ammar R., Kluger J. and White C.M. : "An evaluation of the change in electrocardiographic P-wave variables after acute caffeine ingestion in normal volunteers". J Clin Pharm Ther 2001; 26: 145.

    CrossrefMedlineGoogle Scholar
  • 20. Mostofsky E., Johansen M.B., Lundbye-Christensen S., Tjønneland A., Mittleman M.A. and Overvad K. : "Risk of atrial fibrillation associated with coffee intake: findings from the Danish Diet, Cancer, and Health study". Eur J Prev Cardiol 2016; 23: 922.

    CrossrefMedlineGoogle Scholar
  • 21. Cheng M., Hu Z., Lu X., Huang J. and Gu D. : "Caffeine intake and atrial fibrillation incidence: dose response meta-analysis of prospective cohort studies". Can J Cardiol 2014; 30: 448.

    CrossrefMedlineGoogle Scholar
  • 22. Caldeira D., Martins C., Alves L.B., Pereira H., Ferreira J.J. and Costa J. : "Caffeine does not increase the risk of atrial fibrillation: a systematic review and meta-analysis of observational studies". Heart 2013; 99: 1383.

    CrossrefMedlineGoogle Scholar
  • 23. Klatsky A.L., Hasan A.S., Armstrong M.A., Udaltsova N. and Morton C. : "Coffee, caffeine, and risk of hospitalization for arrhythmias". Perm J 2011; 15: 19.

    CrossrefMedlineGoogle Scholar
  • 24. Mattioli A.V., Bonatti S., Zennaro al. : "The relationship between personality, socio-economic factors, acute life stress and the development, spontaneous conversion and recurrences of acute lone atrial fibrillation". Europace 2005; 7: 211.

    CrossrefMedlineGoogle Scholar
  • 25. Hansson A., Madsen-Hardig B. and Olsson B. : "Arrhythmia-provoking factors and symptoms at the onset of paroxysmal atrial fibrillation: a study-based on interviews with 100 patients seeking hospital assistance". BMC Cardiovasc Disord 2004; 4: 13.

    CrossrefMedlineGoogle Scholar
  • 26. Chelsky L.B., Cutler J.E., Griffith K., Kron J., McClelland J.H. and McAnulty J.H. : "Caffeine and ventricular arrhythmias. An electrophysiological approach". JAMA 1990; 264: 2236.

    CrossrefMedlineGoogle Scholar
  • 27. Myers M.G. : "Caffeine and cardiac arrhythmias". Ann Intern Med 1991; 114: 147.

    CrossrefMedlineGoogle Scholar
  • 28. Graboys T.B., Blatt C.M. and Lown B. : "The effect of caffeine on ventricular ectopic activity in patients with malignant ventricular arrhythmia". Arch Intern Med 1989; 149: 637.

    CrossrefMedlineGoogle Scholar
  • 29. Zuchinali P., Ribeiro P.A., Pimentel M., da Rosa P.R., Zimerman L.I. and Rohde L.E. : "Effect of caffeine on ventricular arrhythmia: a systematic review and meta-analysis of experimental and clinical studies". Europace 2016; 18: 257.

    CrossrefMedlineGoogle Scholar
  • 30. Richardson T., Baker J., Thomas P.W., Meckes C., Rozkovec A. and Kerr D. : "Randomized control trial investigating the influence of coffee on heart rate variability in patients with ST-segment elevation myocardial infarction". QJM 2009; 102: 555.

    CrossrefMedlineGoogle Scholar
  • 31. Zuchinali P., Souza G.C., Pimentel al. : "Short-term effects of high-dose caffeine on cardiac arrhythmias in patients with heart failure: a randomized clinical trial". JAMA Intern Med 2016; 176: 1752.

    CrossrefMedlineGoogle Scholar
  • 32. Newby D.E., Neilson J.M., Jarvie D.R. and Boon N.A. : "Caffeine restriction has no role in the management of patients with symptomatic idiopathic ventricular premature beats". Heart 1996; 76: 355.

    CrossrefMedlineGoogle Scholar
  • 33. O'Keefe J.H., Bhatti S.K., Patil H.R., DiNicolantonio J.J., Lucan S.C. and Lavie C.J. : "Effects of habitual coffee consumption on cardiometabolic disease, cardiovascular health, and all-cause mortality". J Am Coll Cardiol 2013; 62: 1043.

    View ArticleGoogle Scholar
  • 34. Gunter M.J., Murphy N., Cross al. : "Coffee drinking and mortality in 10 European countries: a multinational cohort study". Ann Intern Med 2017; 167: 236.

    CrossrefMedlineGoogle Scholar
  • 35. Myers M.G., Harris L., Leenen F.H. and Grant D.M. : "Caffeine as a possible cause of ventricular arrhythmias during the healing phase of acute myocardial infarction". Am J Cardiol 1987; 59: 1024.

    CrossrefMedlineGoogle Scholar
  • 36. de Vreede-Swagemakers J.J., Gorgels A.P., Weijenberg al. : "Risk indicators for out-of-hospital cardiac arrest in patients with coronary artery disease". J Clin Epidemiol 1999; 52: 601.

    CrossrefMedlineGoogle Scholar
  • 37. Prineas R.J., Jacobs D.R., Crow R.S. and Blackburn H. : "Coffee, tea and VPB". J Chronic Dis 1980; 33: 67.

    CrossrefMedlineGoogle Scholar
  • 38. Zhu J., Zhang X., Li L. and Su G. : "Protective effects of epigallocatechin-3 gallate on atrial electrical and structural remodeling in a rabbit rapid atrial pacing model". Cell Biochem Biophys 2015; 71: 897.

    CrossrefMedlineGoogle Scholar
  • 39. Liu D.C., Yan J.J., Wang al. : "Low-dose green tea intake reduces incidence of atrial fibrillation in a Chinese population". Oncotarget 2016; 7: 85592.

    CrossrefMedlineGoogle Scholar
  • 40. Joukar S., Sheibani V., Koushesh F., Afshar E.G. and Shahrbabaki S.G. : "Arrhythmogenic risk assessment following four-week pretreatment with nicotine and black tea in rat". Res Cardiovasc Med 2015; 4: 27088.

    CrossrefGoogle Scholar
  • 41. Mukamal K.J., Maclure M., Muller J.E., Sherwood J.B. and Mittleman M.A. : "Tea consumption and mortality after acute myocardial infarction". Circulation 2002; 105: 2476.

    CrossrefMedlineGoogle Scholar
  • 42. Zhang C., Qin Y.Y., Wei X., Yu F.F., Zhou Y.H. and He J. : "Tea consumption and risk of cardiovascular outcomes and total mortality: a systematic review and meta-analysis of prospective observational studies". Eur J Epidemiol 2015; 30: 3.

    CrossrefGoogle Scholar
  • 43. Gunja N. and Brown J.A. : "Energy drinks: health risks and toxicity". Med J Aust 2012; 196: 46.

    CrossrefMedlineGoogle Scholar
  • 44. Mangi M.A., Rehman H., Rafique M. and Illovsky M. : "Energy drinks and the risk of cardiovascular disease: a review of current literature". Cureus 2017; 9: 1322.

    Google Scholar
  • 45. Schimpl F.C., da Silva J.F., Gonçalves J.F. and Mazzafera P. : "Guarana: revisiting a highly caffeinated plant from the Amazon". J Ethnopharmacol 2013; 150: 14.

    CrossrefMedlineGoogle Scholar
  • 46. Enriquez A. and Frankel D.S. : "Arrhythmogenic effects of energy drinks". J Cardiovasc Electrophysiol 2017; 28: 711.

    CrossrefMedlineGoogle Scholar
  • 47. Busuttil M. and Willoughby S. : "A survey of energy drink consumption among young patients presenting to the emergency department with the symptom of palpitations". Int J Cardiol 2016; 204: 55.

    CrossrefMedlineGoogle Scholar
  • 48. Alsunni A., Majeed F., Yar T., AlRahim A., Alhawaj A.F. and Alzaki M. : "Effects of energy drink consumption on corrected QT interval and heart rate variability in young obese Saudi male university students". Ann Saudi Med 2015; 35: 282.

    CrossrefMedlineGoogle Scholar
  • 49. Shah S.A., Occiano A., Nguyen al. : "Electrocardiographic and blood pressure effects of energy drinks and Panax ginseng in healthy volunteers: a randomized clinical trial". Int J Cardiol 2016; 218: 318.

    CrossrefMedlineGoogle Scholar
  • 50. Gray B., Ingles J., Medi C., Driscoll T. and Semsarian C. : "Cardiovascular effects of energy drinks in familial long QT syndrome: a randomized cross-over study". Int J Cardiol 2017; 231: 150.

    CrossrefMedlineGoogle Scholar
  • 51. Gray B., Das K.J. and Semsarian C. : "Consumption of energy drinks: a new provocation test for primary arrhythmogenic diseases?". Int J Cardiol 2012; 159: 77.

    CrossrefMedlineGoogle Scholar
  • 52. Fletcher E.A., Lacey C.S., Aaron M., Kolasa M., Occiano A. and Shah S.A. : "Randomized controlled trial of high-volume energy drink versus caffeine consumption on ECG and hemodynamic parameters". J Am Heart Assoc 2017; 6: e004448.

    CrossrefMedlineGoogle Scholar
  • 53. Pommerening M.J., Cardenas J.C., Radwan Z.A., Wade C.E., Holcomb J.B. and Cotton B.A. : "Hypercoagulability after energy drink consumption". J Surg Res 2015; 199: 635.

    CrossrefMedlineGoogle Scholar
  • 54. Worthley M.I., Prabhu A., De Sciscio P., Schultz C., Sanders P. and Willoughby S.R. : "Detrimental effects of energy drink consumption on platelet and endothelial function". Am J Med 2010; 123: 184.

    CrossrefMedlineGoogle Scholar
  • 55. Campbell B., Wilborn C., La Bounty al. : "International Society of Sports Nutrition position stand: energy drinks". J Int Soc Sports Nutr 2013; 10: 1.

    CrossrefMedlineGoogle Scholar
  • 56. Larsson S.C., Drca N., Jensen-Urstad M. and Wolk A. : "Coffee consumption is not associated with increased risk of atrial fibrillation: results from two prospective cohorts and a meta-analysis". BMC Medicine 2015; 13: 207.

    CrossrefMedlineGoogle Scholar
  • 57. Shen J., Johnson V.M., Sullivan al. : "Dietary factors and incident atrial fibrillation: the Framingham Heart Study". Am J Clin Nutr 2011; 93: 261.

    CrossrefMedlineGoogle Scholar
  • 58. Conen D., Chiuve S.E., Everett B.M., Zhang S.M., Buring J.E. and Albert C.M. : "Caffeine consumption and incident atrial fibrillation in women". Am J Clin Nutr 2010; 92: 509.

    CrossrefMedlineGoogle Scholar
  • 59. Mukamal K.J., Hallqvist J., Hammar al. : "Coffee consumption and mortality after acute myocardial infarction: the Stockholm Heart Epidemiology Program". Am Heart J 2009; 157: 495.

    CrossrefMedlineGoogle Scholar
  • 60. Frost L. and Vestergaard P. : "Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study". Am J Clin Nutr 2005; 81: 578.

    CrossrefMedlineGoogle Scholar
  • 61. Wilhelmsen L., Rosengren A. and Lappas G. : "Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors". J Intern Med 2001; 250: 382.

    CrossrefMedlineGoogle Scholar
  • 62. Bertoia M.L., Triche E.W., Michaud al. : "Long-term alcohol and caffeine intake and risk of sudden cardiac death in women". Am J Clin Nutr 2013; 97: 1356.

    CrossrefMedlineGoogle Scholar

Abbreviations and Acronyms


atrial fibrillation and/or flutter


energy drink


Hazard ratio


odds ratio


sudden cardiac death


supraventricular tachycardia


ventricular arrhythmia


ventricular fibrillation


ventricular tachycardia


This research was supported in part by the Victorian Government’s Operational Infrastructure Funding. Dr. Voskoboinik is supported by post-graduate scholarships cofunded by National Health and Medical Research Council (NHMRC) and National Heart Foundation and by Baker IDI Bright Sparks scholarships. Prof. Kalman is supported by an NHMRC practitioner fellowship. The authors have reported that they have no relationships with industry relevant to the contents of this paper to disclose.

William Stevenson, MD, FACC, served as Guest Editor for this paper.

All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Clinical Electrophysiology author instructions page.